Metastatic Urothelial Carcinoma Systemic Second-Line Therapy: The Platinum-Refractory Setting by I. Duran, A. Gómez de Liaño
Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert
every 2 weeks.
New 2020 ESMO Clinical Practice Guidelines now online!
Find all the latest ESMO Guidelines
and
discover the ESMO Guidelines Slide Sets
!
ESMO Members: Access over 800 webcasts & slides , plus medwireNews
Watch video Highlights or Expert Reports , they are open to all!
17 Jan 2020
HER2-positive breast cancer patients who experience cardiotoxicity during trastuzumab therapy may have a long-term risk of cardiopulmonary...
16 Jan 2020
Pathological fractures may herald a poor outcome for adult patients with osteosarcoma of the extremities
15 Jan 2020
Switching to a vegetable-enriched diet does not reduce the likelihood of early prostate cancer progressing
14 Jan 2020
Real-world study shows hypofractionated and conventionally fractionated radiotherapy achieve comparable patient-reported functional outcomes for...
13 Jan 2020
Progression-free survival should not be used as a surrogate for overall survival in clinical trials of advanced ovarian cancer
Riccardo Marconcini discusses some of the current issues in Immuno-Oncology such as pseudoprogression, immune-related response evaluation criteria, decision making on treatment duration, and illustrates the talk with examples from melanoma treatment.
11-14 Dec 2019, Geneva, Switzerland
29-30 Nov 2019, Lugano, Switzerland
28-29 Nov 2019, Zurich, Switzerland
25-26 Nov 2019, Singapore
22-24 Nov 2019, Singapore, Singapore
20-21 Nov 2019, Singapore
20-21 Nov 2019, Singapore
19-21 Nov 2019, Singapore
15-16 Nov 2019, Lugano, Switzerland
14-17 Nov 2019, Vienna, Austria
14-15 Nov 2019, Lisbon, Portugal
07-09 Nov 2019, London, United Kingdom
25-26 Oct 2019, Valencia, Spain
21-22 Oct 2019, Barcelona, Spain
